First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW ORLEANS, June 5, 2026 /PRNewswire/ -- A new study evaluating the role of acmopatide (CT-868), a once-daily dual glucagon-like peptide 1/gastric inhibitory polypeptide receptor...